SEC Filing Summary
Important identification note: The supplied filing is OncoGenex Pharmaceuticals, Inc.’s Form 10-K, not an Achieve Life Sciences filing. It covers the fiscal year ended December 31, 2013; quarterly figures below are for the quarter ended December 31, 2013.
Business context and reporting period
OncoGenex was a clinical-stage biopharmaceutical company developing cancer therapies aimed at treatment resistance. Its pipeline comprised Phase 3 custirsen, Phase 2 apatorsen and preclinical OGX-225. The company had no products approved for sale and no product-sales revenue. Custirsen development was partnered with Teva; the company’s other candidates were not partnered.
Financial results and liquidity
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Collaboration revenue | $29.9 million | $20.1 million |
| Research and development expense | $55.3 million | $39.9 million |
| General and administrative expense | $9.9 million | $7.8 million |
| Net loss | $31.8 million | $21.1 million |
| Loss per share | $2.17 | $1.56 |
| Cash, cash equivalents and short-term investments at year-end | $39.2 million | $75.4 million |
| Total assets / total liabilities at year-end | $55.7 million / $18.5 million | $82.0 million / $15.8 million |
2013 revenue was primarily reimbursement of collaboration-plan expenses by Teva, with the increase mainly related to enrollment and treatment in the AFFINITY trial. R&D spending rose with clinical-trial activity and related staffing and development costs. The company recorded no product revenue and remained loss-making; conventional product gross margins were therefore not applicable.
Cash used in operating activities was $35.9 million in 2013, compared with $43.5 million in 2012. Investing activities provided $32.4 million, mainly from investment maturities, while financing activities provided $10,000. The company reported $8.7 million receivable, mostly unbilled Teva reimbursements. Current assets were $53.9 million and current liabilities $14.9 million at year-end. The filing reports no off-balance-sheet financing arrangements. Long-term obligations were $3.5 million, in addition to current obligations; the filing’s obligation disclosures principally include lease-related commitments.
Fourth quarter, unaudited: Collaboration revenue was $8.6 million, R&D expense $13.2 million, G&A expense $2.4 million, other income $0.4 million and net loss $6.7 million, or $0.45 per share. The comparable 2012 quarter recorded revenue of $9.8 million and net loss of $4.1 million; it included a $1.7 million restructuring gain.
Material changes versus prior period
- Annual collaboration revenue increased by $9.8 million, while R&D expense increased by $15.4 million and net loss widened by $10.8 million.
- Cash and short-term investments fell by $36.2 million, reflecting use of resources to fund operations. Total assets declined by $26.3 million; liabilities increased by $2.7 million, mainly from higher clinical-trial accruals.
- 2012 included $18.3 million of deferred collaboration revenue recognition and a $1.7 million restructuring gain; 2013 revenue mainly reflected reimbursements. Both years’ net results also included noncash warrant revaluation gains ($3.2 million in 2013; $4.5 million in 2012).
Outlook, risks and unusual items
- Management estimated available resources would fund currently planned operations beyond the first quarter of 2015. That estimate depended on assumptions and included expected trial milestones; additional or more costly development could require new financing. Management expected R&D expense to decline slightly in 2014 and beyond.
- SYNERGY’s required death events had been reached; results were blinded pending final review, with results expected by mid-2014. AFFINITY enrollment was expected to finish by year-end 2014; the ENSPIRIT Phase 3 trial continued enrolling. Borealis-1 Phase 2 results were expected in the second half of 2014.
- Key risks included negative or delayed clinical results, regulatory failure, reliance on Teva for custirsen development and reimbursements, financing needs and potential dilution, competition, and dependence on third-party manufacturers and trial operators. Custirsen milestone timing and any associated payments to Isis were uncertain; OncoGenex and Isis disagreed about the applicable share of potential Teva milestone payments.
- The company disclosed a $25 million at-the-market equity facility but had sold no shares under it as of year-end. A $1-percentage-point interest-rate increase was estimated to reduce investment fair value by $0.2 million; a 10% Canadian-dollar appreciation was estimated to affect 2013 results by $0.3 million.
- The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded controls were effective. No material legal proceedings were reported.
Most important facts for investors to verify
- Confirm the issuer and filing match the intended investment: this document is OncoGenex (OGXI), not Achieve Life Sciences.
- Review subsequent disclosures for SYNERGY and Borealis-1 results and for progress, enrollment and costs in AFFINITY and ENSPIRIT.
- Assess cash burn, the collectability and timing of Teva reimbursements, and whether the stated runway assumptions held; verify any later use of the ATM facility or other financing.
- Check the terms and potential financial impact of Teva milestones, royalties, termination rights and disputed or contingent payments to Isis and other licensors.
- Distinguish recurring operating performance from collaboration reimbursements and noncash warrant revaluation gains when evaluating losses and trends.